Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Narazaciclib |
| Synonyms | |
| Therapy Description |
Narazaciclib (ON123300) inhibits CDK4 and ARK5 (NUAK1), resulting in decreased downstream signaling and increased tumor cell death (PMID: 24417566, PMID: 26873845). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Narazaciclib | 7X|ON-123300|ON 123300|ON123300 | CDK4 Inhibitor 18 NUAK1 Inhibitor 3 | Narazaciclib (ON123300) inhibits CDK4 and ARK5 (NUAK1), resulting in decreased downstream signaling and increased tumor cell death (PMID: 24417566, PMID: 26873845). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins FLT3 D835Y | hematologic cancer | sensitive | Narazaciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Narazaciclib (ON123300) inhibited proliferation of cells expressing FLT3-ITD and FLT3 D835Y in culture (PMID: 38641704). | 38641704 |
| FLT3 exon 14 ins FLT3 F691L | hematologic cancer | sensitive | Narazaciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Narazaciclib (ON123300) inhibited proliferation of cells expressing FLT3-ITD and FLT3 F691L in culture (PMID: 38641704). | 38641704 |
| FLT3 exon 14 ins FLT3 D835V | hematologic cancer | sensitive | Narazaciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Narazaciclib (ON123300) inhibited proliferation of cells expressing FLT3-ITD and FLT3 D835V in culture (PMID: 38641704). | 38641704 |
| FLT3 F691L | hematologic cancer | sensitive | Narazaciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Narazaciclib (ON123300) inhibited proliferation of cells expressing FLT3 F691L in culture (PMID: 38641704). | 38641704 |
| FLT3 exon 14 ins FLT3 D835F | hematologic cancer | sensitive | Narazaciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Narazaciclib (ON123300) proliferation of cells expressing FLT3-ITD and FLT3 D835F in culture (PMID: 38641704). | 38641704 |
| FLT3 exon 14 ins | hematologic cancer | sensitive | Narazaciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Narazaciclib (ON123300) inhibited proliferation of cells expressing FLT3-ITD in culture (PMID: 38641704). | 38641704 |
| FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Narazaciclib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Narazaciclib (ON123300) inhibited proliferation of acute myeloid leukemia cell lines harboring FLT3-ITD in culture, and decreased tumor burden in a cell line xenograft model and a patient-derived xenograft (PDX) model (PMID: 38641704). | 38641704 |
| FLT3 exon 14 ins FLT3 Y842H | hematologic cancer | sensitive | Narazaciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Narazaciclib (ON123300) inhibited proliferation of cells expressing FLT3-ITD and FLT3 Y842H in culture (PMID: 38641704). | 38641704 |
| FLT3 exon 14 ins FLT3 N701K | hematologic cancer | sensitive | Narazaciclib | Preclinical - Cell culture | Actionable | In a preclinical study, Narazaciclib (ON123300) inhibited proliferation of cells expressing FLT3-ITD and FLT3 N701K in culture (PMID: 38641704). | 38641704 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04739293 | Phase I | Narazaciclib | Study of ON 123300 in Patients With Advanced Cancer | Recruiting | USA | 0 |
CKB BOOST